Needham Upgrades Globus Medical to Buy, Announces $112 Price Target
Benzinga Newsdesk 9 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Needham analyst David Saxon upgrades Globus Medical (NYSE:GMED) from Hold to Buy and announces $112 price target.
Needham analyst David Saxon upgrades Globus Medical (NYSE:GMED) from Hold to Buy and announces $112 price target.